MHI Funds LLC Sells 353 Shares of Pfizer Inc. (NYSE:PFE)
MHI Funds LLC trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 0.5% during the second quarter, Holdings Channel reports. The firm owned 69,686 shares of the biopharmaceutical company’s stock after selling 353 shares during the period. Pfizer comprises 3.5% of MHI Funds LLC’s holdings, making the stock its 3rd biggest holding. MHI Funds LLC’s holdings in Pfizer were worth $3,019,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Evolution Wealth Advisors LLC bought a new position in shares of Pfizer in the second quarter valued at approximately $34,000. Winch Advisory Services LLC raised its stake in shares of Pfizer by 69.6% in the fourth quarter. Winch Advisory Services LLC now owns 819 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 336 shares during the last quarter. Ruggie Capital Group bought a new position in shares of Pfizer in the fourth quarter valued at approximately $44,000. Contravisory Investment Management Inc. raised its stake in shares of Pfizer by 182.6% in the fourth quarter. Contravisory Investment Management Inc. now owns 1,153 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 745 shares during the last quarter. Finally, Karp Capital Management Corp bought a new position in shares of Pfizer in the fourth quarter valued at approximately $53,000. 71.85% of the stock is currently owned by institutional investors.
In other news, major shareholder Pfizer Inc purchased 50,000 shares of Pfizer stock in a transaction that occurred on Monday, May 13th. The shares were acquired at an average price of $17.00 per share, for a total transaction of $850,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Alexander R. Mackenzie sold 30,000 shares of the stock in a transaction that occurred on Thursday, June 20th. The stock was sold at an average price of $44.00, for a total transaction of $1,320,000.00. Following the sale, the insider now owns 80,094 shares in the company, valued at approximately $3,524,136. The disclosure for this sale can be found here. Company insiders own 0.09% of the company’s stock.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, April 30th. The biopharmaceutical company reported $0.85 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.75 by $0.10. The firm had revenue of $13.12 billion for the quarter, compared to analyst estimates of $13.01 billion. Pfizer had a net margin of 21.31% and a return on equity of 27.48%. The business’s revenue was up 1.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.77 EPS. Research analysts forecast that Pfizer Inc. will post 2.88 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, August 2nd will be given a dividend of $0.36 per share. The ex-dividend date of this dividend is Thursday, August 1st. This represents a $1.44 annualized dividend and a dividend yield of 3.34%. Pfizer’s dividend payout ratio is 48.00%.
Several research analysts recently weighed in on PFE shares. JPMorgan Chase & Co. restated a “sell” rating and issued a $119.00 price objective on shares of Continental in a research report on Tuesday. Morgan Stanley set a $17.00 price objective on shares of BOX and gave the stock a “hold” rating in a research report on Tuesday, June 4th. Credit Suisse Group set a $5.00 price objective on shares of Maxar Technologies and gave the stock a “sell” rating in a research report on Monday, July 15th. Barclays restated a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Thursday, May 9th. Finally, Zacks Investment Research upgraded shares of Green Brick Partners from a “sell” rating to a “hold” rating in a research report on Wednesday, April 10th. Fourteen research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Pfizer presently has a consensus rating of “Hold” and an average price target of $46.47.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Recommended Story: Preferred Stock
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.